Please assess the completion status of the following clinical trial:

Trial Title: FlowTriever Pulmonary Embolectomy Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical signs, symptoms and presentation consistent with acute PE~* PE symptom duration ≤ 14 days~* CTA evidence of proximal PE~* RV/LV ratio ≥ 0.9 without syncope~* Systolic BP ≥ 90 mmHg~* Stable heart rate \<130 BPM prior to procedure~* Patient deemed medically eligible for interventional procedure(s), per institutional guidelines and/or clinical judgment~Exclusion Criteria:~* Thrombolytic use within 30 days of baseline CTA~* Pulmonary hypertension with peak PAP \> 70 mmHg by right heart catheterization~* Vasopressor requirement after fluids to keep pressure ≥ 90 mm Hg~* FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%~* Hematocrit \< 28% within 6 hours of index procedure~* Platelets \< 100,000/µL~* Serum creatinine \> 1.8 mg/dL~* INR \> 3~* Major trauma ISS \> 15~* Presence of intracardiac lead in right ventricle or atrium placed within 6 months~* Cardiovascular or pulmonary surgery within last 7 days~* Actively progressing cancer~* Known bleeding diathesis or coagulation disorder~* Left bundle branch block~* History of severe or chronic pulmonary arterial hypertension~* History of chronic left heart disease with left ventricular ejection fraction ≤ 30%~* History of uncompensated heart failure~* History of underlying lung disease that is oxygen-dependent~* History of chest irradiation~* History of Heparin-induced thrombocytopenia~* Any contraindication to systemic or therapeutic doses of heparin or anticoagulants~* Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated~* Imaging evidence or other evidence that suggests the subject is not appropriate for mechanical thrombectomy intervention~* Life expectancy of \< 90 days~* Female who is pregnant or nursing~* Current participation in another investigational drug or device treatment study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FlowTriever System (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).